Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma
| Status: | Archived |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | December 2009 |
| End Date: | December 2010 |
A Phase I Study Evaluating the Safety, Pharmacokinetics, Tissue Distribution, and Determination of Radiation Dosimetry for 131-I-MIP-1145
This is an open-label, single dose study for patients 18 years of age or older with
confirmed metastatic melanoma. Up to 12 patients will be enrolled and all will receive an
injection of approximately 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145 administered via
IV injection. The study will consist of a single dosing day followed by a 7-day assessment
period and 21-day follow-up period. The total duration of the study from screening to final
follow-up visit is approximately 60 days.
We found this trial at
1
site
3400 Spruce St
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
(215) 662-4000
Hospital of the University of Pennsylvania The Hospital of the University of Pennsylvania (HUP) is...
Click here to add this to my saved trials
